Indrayani Biotech Ltd (526445)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Indrayani Biotech's revenue was ₹37.7 Cr (+29.6% year on year, -48.2% on the previous quarter), and net profit ₹0.5 Cr (+237.5% year on year); the operating margin was 3.9%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹37.7 | +29.6% | -48.2% |
| Operating profit | ₹1.5 | -32.7% | -70.6% |
| Net profit | ₹0.5 | +237.5% | -50.5% |
| EPS (₹) | 0.06 | +200.0% | -75.0% |
| Operating margin | 3.9% | — | — |
📢 Recent Corporate Announcements
Indrayani Biotech Limited has announced the resignation of Mr. K.S. Vaidyanathan (DIN: 01122393) from his position as an Independent Director, effective close of business hours on October 13, 2026. According to the filing, the resignation was tendered on October 12, 2026, due to personal reasons, with confirmation that no other material reasons exist. He holds no directorships or committee memberships in any other listed entities. The Rs 80 crore market cap company reported TTM revenue of Rs 181 crore and PAT of Rs 3 crore.
- Independent Director K.S. Vaidyanathan resigned vide letter dated October 12, 2026
- Board accepted the resignation with effect from close of business hours on October 13, 2026
- Reason cited is personal reasons with no other material reasons confirmed
- Holds Nil directorships and Nil committee memberships in other listed entities
Indrayani Biotech reported consolidated revenue from operations of ₹37.71 crore for Q1 FY27 (ended June 30, 2026), up 29.6% YoY from ₹29.10 crore in Q1 FY26. Consolidated net profit reached ₹0.54 crore compared to ₹0.16 crore in the same period last year. On a standalone basis, revenue fell 37.9% YoY to ₹4.15 crore, while standalone net profit came in at ₹0.15 crore. The company also reconstituted its Audit, Stakeholder Relationship, and Rights Issue Committees.
- Consolidated revenue from operations increased 29.6% YoY to ₹3,770.55 lakhs (₹37.71 crore)
- Consolidated profit after tax stood at ₹54.00 lakhs compared to ₹15.65 lakhs in Q1 FY26
- Profit attributable to owners of the company reported at ₹26.22 lakhs with basic EPS of ₹0.06
- Standalone revenue from operations dropped YoY to ₹415.34 lakhs from ₹668.57 lakhs
- Board approved reconstitution of Audit, Stakeholder Relationship, and Rights Issue Committees
Indrayani Biotech reported consolidated revenue from operations of ₹37.71 crore for Q1 FY27 (ended June 30, 2026), up 29.6% YoY from ₹29.10 crore in Q1 FY26. Consolidated net profit reached ₹0.54 crore compared to ₹0.16 crore in the same period last year. On a standalone basis, revenue fell 37.9% YoY to ₹4.15 crore, while standalone net profit came in at ₹0.15 crore. The company also reconstituted its Audit, Stakeholder Relationship, and Rights Issue Committees.
- Consolidated revenue from operations increased 29.6% YoY to ₹3,770.55 lakhs (₹37.71 crore)
- Consolidated profit after tax stood at ₹54.00 lakhs compared to ₹15.65 lakhs in Q1 FY26
- Profit attributable to owners of the company reported at ₹26.22 lakhs with basic EPS of ₹0.06
- Standalone revenue from operations dropped YoY to ₹415.34 lakhs from ₹668.57 lakhs
- Board approved reconstitution of Audit, Stakeholder Relationship, and Rights Issue Committees
Indrayani Biotech Limited has completed the sale of a 1.83% stake in its subsidiary, Dindigul Farm Product Limited, via the open market on September 30, 2026. Following this divestment, the company's holding in Dindigul Farm Product stands reduced to 27.05%. The subsidiary is a significant contributor to the group, generating Rs 90.04 Cr in turnover, which accounts for 65.33% of consolidated revenues. The exact sale proceeds and consideration amount were not quantified in the filing.
- Divested 1.83% shareholding/control in subsidiary Dindigul Farm Product Limited
- Post-disposal shareholding drops to 27.05%
- Dindigul Farm Product contributed turnover of Rs 90.04 Cr (65.33% of net worth/revenue) during the last financial year
- Transaction executed through open market sales with completion on September 30, 2026
Indrayani Biotech Ltd has scheduled a meeting of its Board of Directors on Wednesday, October 7, 2026. The board will consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. Additionally, the agenda includes a proposal for the reconstitution of various board committees. Investors will look to see if the company sustains its profitability following FY26 net profit of Rs 2.27 Cr.
- Board meeting scheduled for October 7, 2026
- Agenda includes approval of unaudited results for the quarter ended June 30, 2026
- Consolidated and Standalone financial results to be accompanied by Limited Review Report
- Proposal to reconstitute various Committees of the Board of Directors
Indrayani Biotech reported audited standalone revenue of ₹21.90 Cr (₹2,189.78 Lakhs) for FY26, down 42% YoY from ₹37.77 Cr in FY25. Standalone net profit declined 51.6% YoY to ₹0.70 Cr (₹69.97 Lakhs) with EPS dropping to ₹0.15 from ₹0.32 in FY25. Statutory auditors issued a qualified opinion on the consolidated results due to non-Ind AS accounting at two subsidiaries and unconfirmed balances in loans, receivables, and payables. Additionally, standalone cash flow from operations worsened sharply to negative ₹14.10 Cr in FY26.
- Standalone FY26 revenue from operations declined 42% YoY to ₹2,189.78 Lakhs from ₹3,776.91 Lakhs in FY25.
- Standalone net profit fell 51.6% YoY to ₹69.97 Lakhs, leading to an EPS of ₹0.15 compared to ₹0.32 in the previous year.
- Statutory auditors gave a qualified opinion on consolidated results citing Matrix Boilers and Kniss Laboratories reporting under Indian GAAP instead of Ind AS.
- Auditor flagged unconfirmed trade creditors of ₹61.83 Lakhs (41% of total liabilities) in subsidiary HSL Prime Properties.
- Net cash flow from operating activities on a standalone basis deteriorated to -₹1,410.28 Lakhs in FY26 from +₹1,735.34 Lakhs in FY25.
Indrayani Biotech approved its audited consolidated financial results for the quarter and year ended March 31, 2026. For FY26, consolidated revenue stood at Rs 172.84 Cr with a net profit of Rs 2.27 Cr, recovering from a loss of Rs 6.0 Cr in FY25. However, statutory auditors issued a qualified opinion citing Indian GAAP compliance instead of Ind AS for two subsidiaries and unconfirmed balances across loans, receivables, and trade creditors.
- Auditors issued a qualified opinion as two subsidiaries (Matrix Boilers and Kniss Laboratories) prepared financials under Indian GAAP instead of Ind AS.
- Unconfirmed and unreconciled balances flagged across loans, other current assets, and trade receivables.
- Subsidiary HSL Prime Properties lacked balance confirmations for trade creditors worth Rs 61,82,938 (~41% of its liabilities).
- Other auditors covered subsidiaries accounting for ₹11,335.73 lakhs (₹113.36 Cr) in revenue and ₹17,128.01 lakhs in assets.
Indrayani Biotech approved its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, on August 17, 2026. Statutory auditors issued a Qualified Opinion citing unconfirmed balances in loans, other current assets, and trade receivables. Furthermore, two subsidiaries compiled statements under Indian GAAP rather than Ind AS, and another subsidiary lacked confirmation for Rs 61.83 lakh in trade creditors (41% of its liabilities). Other auditors audited entities contributing ₹113.36 Cr in revenue.
- Auditors issued a Qualified Opinion on FY26 consolidated financial statements due to balance reconciliation and Ind AS non-compliance issues.
- Subsidiaries Matrix Boilers and Kniss Laboratories compiled accounts under Indian GAAP instead of Ind AS, with unascertainable P&L impact.
- Subsidiary HSL Prime Properties had unconfirmed trade creditors of Rs 61,82,938 (~41% of its total liabilities).
- Entities audited by other auditors contributed ₹17,128.01 lakhs in assets and ₹11,335.73 lakhs in revenues.
Indrayani Biotech has scheduled a board meeting for August 17, 2026, to approve its audited financial results for the quarter and full year ended March 31, 2026. The company is coming off a difficult period, with TTM losses of Rs 7 crore and a high debt-to-equity ratio of 1.92. Investors will be closely watching for any recovery in operating margins, which stood at 3.0% TTM, and updates on the company's Rs 146 crore debt burden relative to its Rs 57 crore market cap.
- Board meeting scheduled for August 17, 2026, to approve FY26 audited financials
- Company reported TTM revenue of Rs 151 crore against a market capitalization of Rs 57 crore
- Debt levels are significant at Rs 146 crore, nearly double the net worth of Rs 76 crore
- TTM PAT remains negative at Rs -7 crore, following a net loss of Rs 6 crore in FY25
Indrayani Biotech Ltd has received an order from the Central GST Department dated July 15, 2026, revoking the previous cancellation of its GST registration. The registration had been cancelled on June 09, 2026, with retrospective effect from April 28, 2026, due to the non-filing of returns. The revocation order restores the registration from the original cancellation date, allowing the company to resume normal tax-compliant operations. While the company states there was no impact on operations, the initial cancellation highlights a significant lapse in regulatory compliance.
- GST registration restored via revocation order dated July 15, 2026
- Original cancellation was effective from April 28, 2026
- Initial cancellation order was issued on June 09, 2026, for non-filing of returns
- Restoration is retrospective, covering the period from April 28, 2026
- Company claims no impact on operations during the cancellation period
Indrayani Biotech has received a favorable ruling from the Income Tax Appellate Tribunal (ITAT) regarding a tax dispute initiated in March 2025. The ITAT order dated July 14, 2026, quashed the previous order from the First Appellate Authority and remanded the case for fresh adjudication. This follows a series of appeals against an original Assessment Order dated March 26, 2025. While the specific tax demand amount is not disclosed in this filing, the quashing of the previous adverse order provides temporary relief from immediate tax liability enforcement.
- ITAT order dated July 14, 2026, quashes the previous appellate order from March 09, 2026
- Original Assessment Order dates back to March 26, 2025
- Income Tax Appeal No. 1429/CHNY/2026 was filed before the ITAT
- The matter is restored to the First Appellate Authority for fresh adjudication
Indrayani Biotech has received a favorable ruling from the Income Tax Appellate Tribunal (ITAT) regarding a dispute originating from a March 2025 assessment. The ITAT order dated July 14, 2026, quashed a previous unfavorable ruling from the First Appellate Authority dated March 09, 2026. The matter has now been restored to the First Appellate Authority for fresh adjudication. While this provides temporary relief from the previous order, the final tax liability remains unquantified and pending further legal proceedings.
- ITAT order dated July 14, 2026, quashes the previous appellate order issued in March 2026
- The original Assessment Order under dispute dates back to March 26, 2025
- The case (Income Tax Appeal No. 1429/CHNY/2026) has been remanded for fresh adjudication
- The company had previously disclosed updates on this litigation on April 25, 2026
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
